טוען...
Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs
2-(Phosphonomethyl)-pentanedioic acid (2-PMPA) is a potent (IC(50) = 300 pM) and selective inhibitor of glutamate carboxypeptidase II (GCPII) with efficacy in multiple neurological and psychiatric disease preclinical models and more recently in models of inflammatory bowel disease (IBD) and cancer....
שמור ב:
| הוצא לאור ב: | Mol Pharm |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7978038/ https://ncbi.nlm.nih.gov/pubmed/31503493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.9b00637 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|